Celldex culls eczema study after Phase 2 failure
Celldex Therapeutics is dropping its monoclonal antibody as a therapy for eczema after the drug flunked a mid-stage study. The drug, called barzolvolimab, failed to reduce itching in patients with eczema compared with placebo after ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.